The National Institute for Health and Care Excellence (Nice) in the UK has recommended the use of real-time continuous glucose monitoring (rtCGM) or intermittently scanned glucose monitoring (isCGM) devices to treat children with type 2 diabetes.
These two technologies have been selected to replace the ‘burdensome’, ‘tiring’ and ‘stressful’ tasks of finger prick testing and insulin therapy.
Designed to offer a continuous stream of real-time data on a smartphone, both devices were already recommended for children with type 1 diabetes.
The recommendation has been made considering the changes made to NICE’s guidelines concerning the diagnosing and managing of type 1 and type 2 diabetes in children and young people.
A discrete sensor is attached to the body to track both current and past glucose levels. It also provides a prediction of the direction in which glucose levels are heading, enabling individuals to administer insulin and stabilise their levels as required.
NICE has recommended the utilisation of an isCGM device, commonly referred to as flash monitoring, as a substitute for real-time devices.
Research has revealed that both real-time and flash devices enable a person to maintain optimal blood sugar levels.
NICE Clinical Directorate programme director Dr Judith Richardson said: “Type 2 diabetes in children is the most aggressive form of the disease and recommending new technology is a clear step towards giving children on insulin therapy the ability to manage their own condition in a less invasive way and to live happier and healthier lives.
“Improvements made in managing a child’s diabetes at an early stage can reduce the health impact of the condition later in their lives and the potential impact on the health service.”